1. Scrip
  2. >>Therapy Areas
  3. >>Dermatological

Pfizer’s Abrocitinib Quick Off The Mark In Atopic Dermatitis

Top-Line Results From Third Phase III Study

 
• By John Davis

Pfizer’s next-generation JAK1 inhibitor, abrocitinib, continues to show beneficial effects in atopic dermatitis (eczema), in the JADE COMPARE study, comparable to the positive control dupilumab and, in the case of itch, with a faster onset at the higher dose.  

Starting_Blocks
• Source: Shutterstock

Pfizer Inc.’s next-generation oral JAK1 inhibitor, abrocitinib, is likely to be a strong competitor to Sanofi/Regeneron Pharmaceuticals Inc.’s Dupixent (dupilumab) for treating atopic dermatitis, judging by top-line results from a third Phase III study which showed a higher dose of abrocitinb was significantly superior to the interleukin-4/IL-13 inhibitor, dupilumab, in reducing itch after the first two weeks of therapy.

Having a quicker effect on symptoms could be an important differentiator for abrocitinib in its likely marketing battle with the entrenched dupilimab, which has established a leading position in the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

InflaRx Stock Sinks As Vilobelimab Fails Phase III Skin Trial

 
• By Kevin Grogan

A study of the German biotech's intravenous complement factor C5a antibody for pyoderma gangrenosum was stopped for futility.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Abeona Sets $3.1m Price For Rare Skin Disorder Gene Therapy

 
• By Joseph Haas

Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

More from Therapy Areas

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.

Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

 
• By Jessica Merrill

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise

 
• By Andrew McConaghie

The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.